We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

74 hedge funds and large institutions have $100M invested in Gyre Therapeutics in 2013 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $2.04M | Put options by funds: $1.02M

20% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 20

0% more funds holding

Funds holding: 74 → 74 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 14

25% less capital invested

Capital invested by funds: $135M → $100M (-$34.1M)

Holders
74
Holders Change
–
Holders Change %
0%
% of All Funds
2.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
24
Reduced
20
Closed
14
Calls
$2.04M
Puts
$1.02M
Net Calls
+$1.01M
Net Calls Change
+$4.36M

Top Buyers

1
DM
Deerfield Management
New York
+$3.09M
2
BIT
BlackRock Institutional Trust
California
+$1.5M
3
BC
Broadfin Capital
New York
+$1.5M
4
Goldman Sachs
Goldman Sachs
New York
+$1.1M
5
CCM
Camber Capital Management
Massachusetts
+$926K

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$11M
2
BFA
BlackRock Fund Advisors
California
-$1.99M
3
Deutsche Bank
Deutsche Bank
Germany
-$1.79M
4
Millennium Management
Millennium Management
New York
-$1.17M
5
HVC
Healthcare Value Capital
New Jersey
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$25.6M – – –
NMC
2
NEA Management Company
Maryland
$19M -$31.5K -8 -0.1%
BIT
3
BlackRock Institutional Trust
California
$6.3M +$1.5M +381 +25%
Franklin Resources
4
Franklin Resources
California
$5.21M +$402K +102 +7%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$3.88M +$891K +226 +23%
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.81M +$363K +92 +9%
BFA
7
BlackRock Fund Advisors
California
$3.24M -$1.99M -505 -34%
Jennison Associates
8
Jennison Associates
New York
$2.89M +$11.8K +3 +0.3%
DM
9
Deerfield Management
New York
$2.56M +$3.09M +783 New
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$2.3M +$398K +101 +17%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$2.19M +$94.6K +24 +4%
State Street
12
State Street
Massachusetts
$1.91M +$15.8K +4 +0.7%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$1.78M +$63.1K +16 +3%
Goldman Sachs
14
Goldman Sachs
New York
$1.66M +$1.1M +279 +122%
Northern Trust
15
Northern Trust
Illinois
$1.62M +$39.4K +10 +2%
SFM
16
Sphera Funds Management
Israel
$1.25M +$1.5M +381 New
BC
17
Broadfin Capital
New York
$1.24M +$1.5M +380 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$988K +$118K +30 +11%
Millennium Management
19
Millennium Management
New York
$970K -$1.17M -297 -50%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$788K – – –
CCM
21
Camber Capital Management
Massachusetts
$768K +$926K +235 New
Deutsche Bank
22
Deutsche Bank
Germany
$681K -$1.79M -454 -68%
BGA
23
Belmont Global Advisors
Texas
$643K +$777K +197 New
TC
24
TFS Capital
Pennsylvania
$641K +$166K +42 +27%
Renaissance Technologies
25
Renaissance Technologies
New York
$594K -$855K -217 -54%
1
2 3 4

GYRE Hedge Fund Activity: Q4 2013 in Review

74 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2013, worth a combined $100M — down 25% from $135M a quarter earlier.

Fund positioning in GYRE was balanced in Q4 2013: 14 funds opened new positions, 14 closed out, 24 added to existing stakes and 20 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $3.09M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $11M sold.

  • 74 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2013, unchanged from Q3 2013.
  • Funds reported $100M of Gyre Therapeutics stock for Q4 2013, down 25% quarter-over-quarter.
  • 14 funds opened new Gyre Therapeutics positions in Q4 2013 and 14 closed out, a net change of 0 holders.
  • The largest Gyre Therapeutics buyer in Q4 2013 was Deerfield Management, an estimated $3.09M added.
  • The largest Gyre Therapeutics seller in Q4 2013 was Baker Bros. Advisors, an estimated $11M sold.

Based on aggregated 13F filings for Q4 2013.